E-cigarettes versus NRT for smoking reduction or cessation in people with mental illness: secondary analysis of data from the ASCEND trial

Tobacco Induced Diseases

Christopher Bullen¹  Varsha Parag¹  Natalie Walker¹  Oliver Knight-West¹  Brigid O’Brien¹ 

[1] National Institute for Health Innovation, School of Population Health, The University of Auckland, Auckland, New Zealand

关键词: Harm reduction;    Nicotine;    Mental illness;    Smoking cessation;    Tobacco;    Electronic cigarette/e-cigarette;   

Others  :  1159076
DOI  :  10.1186/s12971-015-0030-2

 received in 2014-09-22, accepted in 2015-03-04,  发布年份 2015

【 摘 要 】

Background

People with mental illness have higher rates of smoking than the general population and are at greater risk of smoking-related death and disability. In smokers from the general population, electronic cigarettes (e-cigarettes) have been shown to have a similar effect on quit rates as nicotine replacement therapy, but little is known about their effect in smokers with mental illness.

Methods

Secondary analysis of data from the ASCEND trial involving 657 dependent adult smokers motivated to quit, randomised to 16 mg nicotine e-cigarette, 21 mg nicotine patch, or 0 mg nicotine e-cigarette, with minimal behavioural support. Using self-reported medication use and the Anatomical Therapeutic Chemical Classification System, we identified 86 participants with mental illness and analysed their cessation and smoking reduction outcomes.

Results

For e-cigarettes alone, and all interventions pooled, there was no statistically significant difference in biochemically verified quit rates at six months between participants with and without mental illness, nor in smoking reduction, adverse events, treatment compliance, or acceptability. Rates of relapse to smoking were higher in participants with mental illness. Among this group, differences between treatments were not statistically significant for cessation (patch 14% [5/35], 16 mg e-cigarette 5% [2/39], 0 mg e-cigarette 0% [0/12], p = 0.245), adverse events or relapse rates. However, e-cigarette users had higher levels of smoking reduction, treatment compliance, and acceptability.

Conclusions

The use of e-cigarettes for quitting appears to be equally effective, safe, and acceptable for people with and without mental illness. For people with mental illness, e-cigarettes may be as effective and safe as patches, yet more acceptable, and associated with greater smoking reduction.

Trial registration

Australian New Zealand Clinical trials Registry, number: ACTRN12610000866000 webcite.

【 授权许可】

   
2015 O'Brien et al.; licensee BioMed Central.

【 参考文献 】

• [1]Brown S, Inskip H, Barraclough B: Causes of the excess mortality of schizophrenia. Br J Psychiatry 2000, 177:212-7.
• [2]Banham L, Gilbody S: Smoking cessation in severe mental illness: what works? Addiction 2010, 105(7):1176-89.
• [3]Campion J, Checinski K, Nurse J, McNeill A: Smoking by people with mental illness and benefits of smoke-free mental health services. Adv Psychiatr Treat 2008, 14:217-28.
• [4]Smith PH, Homish GG, Giovino GA, Kozlowski LT: Cigarette smoking and mental illness: a study of nicotine withdrawal. Am J Public Health 2014, 104(2):e127-33. doi:10.2105/ajph.2013.301502
• [5]Smith PH, Mazure CM, McKee SA: Smoking and mental illness in the US population. Tob Control 2014, 23(e2):e147-53. doi:10.1136/tobaccocontrol-2013-051466
• [6]Callaghan RC, Veldhuizen S, Jeysingh T, Orlan C, Graham C, Kakouris G, et al.: Patterns of tobacco-related mortality among individuals diagnosed with schizophrenia, bipolar disorder, or depression. J Psychiatr Res 2014, 48(1):102-10.
• [7]Centers for Disease Control and Prevention: Vital signs: Current cigarette smoking among adults aged aged ≥ 18 Years—United States, 2009–2011 MMWR Morb Mortal Wkly Rep 2013, 62(5):81-7.
• [8]Wittchen HU, Jacobi F: Size and burden of mental disorders in Europe—a critical review and appraisal of 27 studies. Eur Neuropsychopharmacol 2005, 15:357-76.
• [9]McManus S, Meltzer H, Brugha T, Bebbington P, Jenkins R. Adult Psychiatric Morbidity Survey 2007. Results of a household survey. The NHS Health & Social Care Information Centre, Social Care Statistics; 2009. http://www.hscic.gov.uk/catalogue/PUB02931/adul-psyc-morb-res-hou-sur-eng-2007-rep.pdf
• [10]McCreadie R, Kelly C: Patients with schizophrenia who smoke. Private disaster, public resource. Br J Psychiatry 2000, 176:109.
• [11]Siru R, Hulse GK, Tait RJ: Assessing motivation to quit smoking in people with mental illness: a review. Addiction 2009, 104(5):719-33.
• [12]Tsoi DT, Porwal M, Webster AC: Interventions for smoking cessation and reduction in individuals with schizophrenia. Cochrane Database Syst Rev 2013, 2:CD007253. doi:10.1002/14651858.CD007253.pub3
• [13]Pachas G, Cather C, Pratt S, Hoeppner B, Nino J, Carlini S, et al.: Varenicline for smoking cessation in schizophrenia: safety and effectiveness in a 12-week, open-label trial. J Dual Diagn 2012, 8(2):1178-125.
• [14]Rüther T, Bobes J, De Hert M, Svensson TH, Mann K, Batra A, et al.: EPA Guidance on tobacco dependence and strategies for smoking cessation in people with mental illness. Eur Psychiatry 2014, 29(2):65-82. http://dx.doi.org/10.1016/j.eurpsy.2013.11.002
• [15]van der Meer RM, Willemsen MC, Smit F, Cuijpers P: Smoking cessation interventions for smokers with current or past depression. Cochrane Database Syst Rev 2013, 8:CD006102. doi:10.1002/14651858.CD006102.pub2
• [16]Kishi T, Iwata N. Varenicline for smoking cessation in people with schizophrenia: systematic review and meta-analysis. Eur Arch Psychiatry Clin Neurosci. 2014. doi:10.1007/s00406-014-0551-3
• [17]Parker C, McNeill A, Ratschen E: Tailored tobacco dependence support for mental health patients: a model for inpatient and community services. Addiction 2012, 107(Suppl 2):18-25.
• [18]Royal College of Physicians: Smoking and Mental Health. RCP, London; 2013.
• [19]Cook BL, Wayne GF, Kafali EN, Liu Z, Shu C, Flores M: Trends in smoking among adults with mental illness and association between mental health treatment and smoking cessation. JAMA 2014, 311(2):172-82. doi:10.1001/jama.2013.284985
• [20]Caponnetto P, Campagna D, Cibella F, Morjaria J, Caruso M, Russo C, et al.: Efficiency and Safety of an electronic cigarette (ECLAT) as tobacco cigarettes substitute: a prospective 12-month randomized control design study. PLoS One 2013, 8(6):e66317. doi:10.1371/journal.pone.0066317
• [21]Bullen C, Howe C, Laugesen M, McRobbie H, Parag V, Williman J, et al.: Electronic cigarettes for smoking cessation: a randomised controlled trial. Lancet 2013, 382(9905):1629-37. http://dx.doi.org/10.1016/S0140-6736(13)61842-5
• [22]Adriaens K, Van Gucht D, Declerck P, Baeyens F: Effectiveness of the electronic cigarette: an eight-week flemish study with six-month follow-up on smoking reduction, craving and experienced benefits and complaints. Int J Environ Res Public Health 2014, 11(11):11220-48. doi:10.3390/ijerph111111220.23
• [23]Caponnetto P, Auditore R, Russo C, Cappello GC, Polosa R: Impact of an electronic cigarette on smoking reduction and cessation in schizophrenic smokers: a prospective 12-month pilot study. Int J Environ Res Public Health 2013, 10(2):446-61. http://dx.doi.org/10.3390/ijerph10020446
• [24]Caponnetto P, Polosa R, Russo C, Leotta C, Campagna D: Successful smoking cessation with electronic cigarettes in smokers with a documented history of recurring relapses: a case series. J Med Case Rep 2011, 5:585. BioMed Central Full Text
• [25]Caponnetto P, Polosa R, Auditore R, Russo C, Campagna D: Smoking cessation with e-cigarettes in smokers with a documented history of depression and recurring relapses. Int J Clin Med 2011, 2:281-4.
• [26]Schneiderhan M: A case report of patient-initiated e-cigarette use and resulting 5-months smoking cessation. J Pharm Pract 2012, 25(2):297.
• [27]Cummins SE, Zhu S-H, Tedeschi GJ, Gamst AC, Myers MG: Use of e-cigarettes by individuals with mental health conditions. Tob Control 2014, 23(suppl 3):iii48-53. doi:10.1136/tobaccocontrol-2013-051511
• [28]Prochaska JJ, Grana RA: E-Cigarette Use among Smokers with Serious Mental Illness. PLoS One 2014, 9(11):e113013.
• [29]Bullen C, Williman J, Howe C, Laugesen M, McRobbie H, Parag V, et al.: Study protocol for a randomised controlled trial of electronic cigarettes versus nicotine patch for smoking cessation. BMC Public Health 2013, 13:210. doi:10.1186/471-2458-13-210 BioMed Central Full Text
• [30]WHO Collaborating Centre for Drug Statistics Methodology. ATC structure and principles. 2011. [cited 2013 29/11/13]; Available from: http://www.webcitation.org/6LTkY7A7C.
• [31]Heatherton T, Kozlowski L, Frecker R, Fagerstrom K: The fagerstrom test for nicotine dependence: a revision of the fagerstrom tolerance questionnaire. Br J Addict 1991, 86(9):1119-27.
• [32]Glover ED, Nilsson F, Westin A, Glover PN, Laflin MT, Persson B: Developmental history of the Glover-Nilsson smoking behavioral questionnaire. Am J Health Behav 2005, 29(5):443-55. doi:10.5555/ajhb.2005.29.5.443
• [33]DiFranza JR, Wellman RJ, Ursprung WW, Sabiston C: The autonomy over smoking scale. Psychol Addict Behav 2009, 23(4):656-65. doi:10.1037/a0017439
• [34]Hajek P. Electronic cigarettes for smoking cessation. Lancet. 2013. http://dx.doi.org/10.1016/S0140-6736(13)61534-2.
• [35]NICE. National Institute for Health and Clinical Excellence (NICE). Tobacco: harm-reduction approaches to smoking. PH45. 2013 01-Dec-2014; Available from: https://www.nice.org.uk/guidance/ph45.
• [36]Wilson N, Weerasekera D, Collings S, Edwards R, Deen FS: Poorer mental health in many New Zealand smokers: national survey data from the ITC Project. N Z Med J 2010, 123(1326):129-32.